Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications Pharmaceutical TechnologyThe FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for two new indications in HER2-positive early breast cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Technology The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Arna Pharma and Slate Run complete JV for new US companyNext: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
